Cat. No.: HY-D1056A1

Lipopolysaccharides, from E. coli O111:B4

(Synonyms: LPS, from Escherichia coli (O111:B4))

6 Cited Publications

Customer Review

Based on 6 publication(s) in Google Scholar

Lipopolysaccharides, from E. coli O111:B4 (LPS, from Escherichia coli (O111:B4)) are endotoxins and TLR4 activators extracted from Escherichia coli (E. coli O111:B4) and are classified as S (smooth) type LPS. Lipopolysaccharides (LPS), from E. coli O111:B4 possess the typical three-part structure: O-antigen, R3-type core oligosaccharide, and lipid A. Lipopolysaccharides (LPS), from E. coli O111:B4 activate TLR-4 in immune cells and can cause significant gastric diseases. Lipopolysaccharides (LPS), from E. coli O111:B4 can be used to induce cellular inflammation and establish animal models related to inflammation.
It is recommended to prepare a solution with concentration ≥2 mg/mL. Vortex thoroughly for more than 10 minutes. Due to the adsorption characteristics of LPS, silanized container or low adsorption centrifuge tubes should be used for aliquoting and storage, and mix thoroughly before use.

For research use only. We do not sell to patients.

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Lipopolysaccharides, from E. coli O111:B4 Chemical Structure

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
- Induced Disease Models
Chemical Information
Publications (6)
Solvent & Solubility
- In Vitro
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

Lipopolysaccharides, from E. coli O111:B4 (LPS, from Escherichia coli (O111:B4)) are endotoxins and TLR4 activators extracted from Escherichia coli (E. coli O111:B4) and are classified as S (smooth) type LPS. Lipopolysaccharides (LPS), from E. coli O111:B4 possess the typical three-part structure: O-antigen, R3-type core oligosaccharide, and lipid A. Lipopolysaccharides (LPS), from E. coli O111:B4 activate TLR-4 in immune cells and can cause significant gastric diseases. Lipopolysaccharides (LPS), from E. coli O111:B4 can be used to induce cellular inflammation and establish animal models related to inflammation^[1]^[2]^[3]^[4]^[5]^[6]^[7]^[8]^[9].
It is recommended to prepare a solution with concentration ≥2 mg/mL. Vortex thoroughly for more than 10 minutes. Due to the adsorption characteristics of LPS, silanized container or low adsorption centrifuge tubes should be used for aliquoting and storage, and mix thoroughly before use.

IC₅₀ & Target

TLR-4^[2]

All Toll-like Receptor (TLR) Isoforms :

In Vitro

Note:
1. Concentration and Time: Please do not rely solely on a single article to determine experimental conditions. It is recommended to review relevant literature based on the cell line and type of LPS before formal experiments, as the required induction time or optimal concentration for different inflammatory factors to reach their peak may vary. It is advisable to set concentration and time gradients to identify the optimal experimental scheme.
2. Detection Indicators: LPS does not necessarily induce cell death; therefore, it is not appropriate to determine the LPS modeling concentration and time solely by assessing cell viability. It is recommended to measure the expression or secretion of inflammatory factors.
3. Solvent Selection: Literature indicates that certain concentrations of DMSO can significantly inhibit LPS-induced inflammatory responses. In cellular experiments, it is recommended to prepare stock solutions using sterile water, followed by dilution with culture medium.
4. Container Selection: Due to the adsorption characteristics of LPS, it can bind to plastics and certain types of glass (especially at concentrations <0.1 mg/mL). The adsorption effect is relatively small when LPS concentrations exceed 1 mg/mL. Additionally, LPS tends to form micelles in solution. Therefore, when dissolving the powder, it is recommended to prepare concentrations of ≥2 mg/mL, and to vortex thoroughly for more than 10 minutes. If necessary, ultrasonic assistance may be used. For storage, please use silanized containers or low-adhesion centrifuge tubes. If glass containers are used, ensure to mix thoroughly for at least 30 minutes prior to use to re-dissolve any LPS adsorbed to the wall of the container.
5. Concentration Units: LPS does not have a uniform molecular weight because its molecules exhibit heterogeneity and aggregation. The molecular weight of naturally sourced LPS typically ranges from 10-100 kDa or even higher. Common dosing concentrations for LPS found in the literature are in terms of mass concentration, such as ng/mL and μg/mL, so it is sufficient to prepare solutions directly in mass concentration during experiments.
6. Filtration Sterilization: After dissolving LPS powder in water, saline, or PBS, the solution may appear turbid or colloidal, and in some cases, a microsphere distribution with diameters around 20-30 nm may be observed. When sterilizing by filtration, do not filter the stock solution directly. It is recommended to dilute to working solution first and then filter sterilize through a 0.22 μm filter membrane.
7. Differences Among Different Strain LPS: LPS of different catalog numbers comes from various bacterial strains, corresponding to different structural features such as lipid A, core polysaccharides, and O-antigens, which in turn affect the intensity of inflammation induction and TLR4-mediated signaling bias. Commonly referenced LPS catalog numbers for in vitro or in vivo inflammation model construction include HY-D1056 and HY-D1056A1. Moreover, in specific research contexts, specialized sources of LPS related to the studied bacterial strains may also be used. For example, HY-D1056D (from Porphyromonas gingivalis) is used in periodontal studies, while HY-D1056B3 (from Klebsiella pneumoniae) is relevant in pneumonia-related research. When selecting LPS, considerations should include the purpose of the experiment, sensitivity of the cell line, and other factors.

LPS is the major toxic component of Gram-negative bacteria, capable of activating pathogen-associated molecular patterns (PAMP) of the immune system and inducing cellular secretion of migrasomes. LPS can be recognized by TLR4, activating the innate immune system, followed by promoting NF-κB activation and the production of pro-inflammatory cytokines, commonly used in experiments for the stimulation, activation, and differentiation of immune cells.
Different types of bacteria express LPS with varying structures and biological activities. LPS generally comes in two configurations: R (rough) type and S (smooth) type. S-type LPS contains a typical three-part structure: O-antigen (O-antigen) (serum-specific polysaccharides composed of repeating oligosaccharide units), core oligosaccharide (core) (C9-type non-repeating oligosaccharides), and lipid A (Lipid A) (the toxic component of LPS). The R type does not contain an O-antigen and expresses rough-type LPS. The lack of O-antigen can affect how immune cells recognize LPS.
E. coli expresses four LPS serotypes: O111:B4, O55:B5, O127:B8, O128:B12. The LPS expressed by the E. coli O111:B4 strain is known to cause significant gastrointestinal diseases and is the most cited LPS strain in literature. LPS derived from E. coli O111:B4 can induce polarization of human macrophages (M1)^[5].

1. Induction of cellular inflammation model^[6]^[7]

Background

LPS binds to the TLR4-MD-2 complex on the cell surface, activates both MyD88-dependent and MyD88-independent signaling pathways, promotes the translocation of transcription factors such as NF-κB into the nucleus, triggers the expression of inflammation-related genes, and leads to the occurrence of an inflammatory response in cells.

Specific Modeling Methods

Cell: Macrophages, tumor cells, glial cells and so on.
Administration: 0.1-10 μg/mL • 1-24 h

Note

(1) Before the formal experiment, relevant references should be consulted according to the cell line and the source of LPS, etc., and concentration and time gradients should be screened to determine the optimal experimental protocol.
(2) Stimulating cells with LPS does not necessarily lead to cell death. Therefore, it is not appropriate to determine the concentration and time of LPS for establishing the model merely by detecting cell viability. It is recommended to detect the expression and secretion of multiple inflammatory factors.
(3) During the process of stimulating cells with LPS, the morphological changes of cells should be observed regularly. An excessively high concentration may cause cytotoxicity, while an excessively low concentration may fail to effectively damage the cells.
(4) A certain concentration of DMSO can significantly inhibit the inflammatory response induced by LPS. It is recommended to dissolve LPS in PBS or ddH₂O.
(5) In the research on the construction of in vitro inflammatory models, Lipopolysaccharides, from E. coli O55:B5 (HY-D1056) and Lipopolysaccharides, from E. coli O111:B4 (HY-D1056A1) are the most widely used LPS, and they are highly recommended!

Modeling Indicators

The secretion/expression of inflammatory factors such as IL-1β, IL-6 and TNF-α in the supernatant or cells increases.
The release of NO increases.
The expression of inflammatory genes such as iNOS, NF-κB and NLRP3 increases.

Correlated Product(s) Lipopolysaccharides, from E. coli O55:B5 (HY-D1056)

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Induced Disease Models

Note:
Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.

Guidelines for Establishing In Vivo Animal Models with LPS

Animal Models	Recommended LPS Types	Reference Doses and Management Methods (Taking Mice as an Example)	Recommended Detection Indicators
Sepsis (Shock) Model [PMID: 26440998; 27127234; 19529910]	LPS, from E. coli O111:B4 (HY-D1056A1) LPS, from E. coli O55:B5 (HY-D1056) LPS, from E. coli O127:B8 (HY-D1056A2)	2.5-10 mg/kg; Intraperitoneal injection	Assessment of Inflammatory Mediators: TNF-α, IL-6, IL-1β, etc. (ELISA detection of Serum/Plasma). Histopathological Evaluation: HE staining of the kidney, glomerular cell proliferation, epithelial cell degeneration and necrosis, interstitial inflammatory cell infiltration, etc. Others: Serum Scr, BUN (markers of renal filtration function).
Cardiac Dysfunction/Myocarditis Model [PMID: 32896106; 36593471]	LPS, from E. coli O111:B4 (HY-D1056A1) LPS, from E. coli O55:B5 (HY-D1056)	10 mg/kg; Intraperitoneal injection	Assessment of Inflammatory Mediators: TNF-α, IL-6, IL-1β, etc. (ELISA detection of Serum/Plasma). Histopathological Evaluation: HE staining of the heart, disordered arrangement of myocardial fibers, destruction of myocardial tissue, unclear contour, myocardial dissolution, interstitial edema, congestion, inflammatory cell infiltration, etc. Others: Echocardiographic detection of dysfunction.
Acute Lung Injury Model [PMID: 31595149; 26888116; 20975550]	LPS, from E. coli O111:B4 (HY-D1056A1) LPS, from E. coli O55:B5 (HY-D1056) LPS, from Klebsiella pneumonia (HY-D1056B3)	0.2-15 mg/kg; Intratracheal administration	Assessment of Inflammatory Mediators: TNF-α, IL-6, IL-1β, etc. (ELISA/qPCR detection of BALF/lung tissue). Histopathological Evaluation: HE staining of the Lung, leukocyte infiltration in alveoli, thickening of alveolar walls, plaque hemorrhage and interstitial edema, etc. Others: Lung dry/wet ratio (D/W ratio).
Acute Liver Injury Model [PMID: 27127234; 36849063]	LPS, from E. coli O111:B4 (HY-D1056A1) LPS, from E. coli O55:B5 (HY-D1056)	5-50 μg/kg + D-GalN (200-400 mg/kg); Intraperitoneal injection	Assessment of Inflammatory Mediators: TNF-α, IL-6, IL-1β, etc. (ELISA/qPCR detection of serum/liver tissue). Histopathological Evaluation: HE staining of the liver, liver structural disorder, hemorrhagic plaques, inflammatory cell infiltration, etc. Others: Serum ALT, AST (markers of liver injury).
Periodontitis Model [PMID: 23167849; 27987467]	LPS, from P. gingivalis (HY-D1056D) LPS, from E. coli O55:B5 (HY-D1056)	4-10 μg; 2-4 times; Oral periodontal tissue injection	Assessment of Inflammatory Mediators: iNOS, COX-2, TNF-α, IL-6, etc. (qPCR detection of gingival tissue). Histopathological Evaluation: HE staining of gingival/alveolar bone tissue, Inflammatory cells infiltrate, and collagen fiber bundles are loosely distributed near the tissue-root interface. Others: The number of immune cells in gingival tissue (flow cytometry).
Encephalitis Model [PMID: 35858866; PMID: 36240654]	LPS, from E. coli O111:B4 (HY-D1056A1) LPS, from P. gingivalis (HY-D1056D)	3-5 mg/kg; Intraperitoneal injection	Assessment of Inflammatory Mediators: IL-1β, IL-6, TNF-α, etc. (qPCR/WB detection of brain/hippocampus tissue). Immunofluorescence Detection: IBA-1 (Microglia marker); GFAP (Astrocyte marker); Siglec-E, etc.
Depression Model [PMID: 31327964; 38677623]	LPS, from E. coli O111:B4 (HY-D1056A1) LPS, from E. coli O55:B5 (HY-D1056)	5-10 mg/kg; Intraperitoneal injection	Assessment of Inflammatory Mediators: IL-1β, NLRP3, Caspase-1, etc. (qPCR/WB detection of hippocampus/cortex); IL-6, IL-1β, TNF-α, etc. (ELISA detection of hippocampus/cortex/serum). Immunofluorescence Detection: IBA-1, GFAP, etc. Behavioral Tests/Detection: Tail suspension experiments and forced swimming experiments, etc., has a longer time of immobility and a shortened latency period of immobility.
Parkinson's Model [PMID: 35065246; 30455692]	LPS, from E. coli O111:B4 (HY-D1056A1) LPS, from P. gingivalis (HY-D1056D)	2-5 μg; Black matter injection	Assessment of Inflammatory Mediators: iNOS, COX-2, etc. ( WB detection of substantia nigra); TNF-α, IL-1β, IL-6, etc. (ELISA/qPCR detection of substantia nigra). Immunofluorescence Assay/Detection: IBA-1, GFAP, etc. Behavioral Tests/Detection: Rotational behavior test, significantly increased number of rotations; Open field test, bradykinesia, reduced exploratory drive in novel environment, preference for peripheral zone activity; Rotarod test, shortened retention time, premature fall latency. Others: Cx43, Tyrosine hydroxylase (WB detection of substantia nigra).

Lipopolysaccharides, from E. coli O55:B5 (HY-D1056) can be used to induce cell and animal models related to inflammation. Among them, the animal models include sepsis (shock) model, cardiac dysfunction/myocarditis model, acute lung injury model, acute liver injury model, encephalitis model, depression model, etc. The following are examples of several models:

1. Induction of septic shock/sepsis model^[8]

Background

After entering the body, LPS is recognized by TLR4, which activates the relevant signaling pathways and triggers the massive release of inflammatory mediators. This, in turn, leads to a series of pathophysiological changes such as the out-of-control inflammatory response, vascular endothelial injury, and activation of the coagulation system, ultimately inducing the occurrence of sepsis (septic shock).

Specific Modeling Methods

C57BL/6 mice • 2.5-10 mg/kg • i.p.

Note

(1) Before inducing an animal model with LPS, relevant references should be consulted based on the experimental purpose, animal type, etc., and preliminary experiments should be conducted to determine the optimal experimental protocol.
(2) After LPS administration, the time points at which the peak levels of different inflammatory factors appear may vary. It is recommended to determine the experimental protocol according to references, and multiple time points should be selected for detection during preliminary experiments.
(3) LPS should be stored away from light and avoid repeated freezing and thawing.

Modeling Indicators

The secretion of TNF-α, IL-6, IL-1β, etc. in the serum/plasma increases.
HE staining of the kidney: proliferation of glomerular cells, degeneration and necrosis of epithelial cells, infiltration of interstitial inflammatory cells, etc.
The levels of Scr and BUN (markers of renal filtration function) increase.

Correlated Product(s): Lipopolysaccharides, from E. coli O55:B5 (HY-D1056)

2. Induction of acute liver failure model^[8]^[9]

Background

LPS is often used in combination with D-galactosamine (D-GalN) to induce an acute liver injury model. LPS activates the immune system and triggers an inflammatory response, while D-galactosamine causes metabolic disorders in hepatocytes and increases their sensitivity to damaging factors. Through the synergistic effect of the two, acute liver injury is induced via mechanisms such as the attack of inflammatory mediators.

Specific Modeling Methods

C57BL/6 mice • 5-50 μg/kg + D-GalN (200-400 mg/kg) • i.p.

Modeling Indicators

The secretion or expression of TNF-α, IL-6 and IL-1β increases in the serum or liver tissue.
HE staining of the liver: disordered liver structure, bleeding plaques, infiltration of inflammatory cells, etc.
The levels of ALT and AST (markers of liver injury) increase significantly.

Correlated Product(s): Lipopolysaccharides, from E. coli O55:B5 (HY-D1056)

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

Appearance Solid
Color White to off-white
SMILES

[Lipopolysaccharides, from E. coli O111:B4]
Synonyms

LPS, from Escherichia coli (O111:B4)
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (6)

All RT-PCRCell Imaging/StainingCell Migration/Invasion AssayFlow CytometryWB

Sort by:

Journal Impact Factor

Cell Rep Med

Artificial exosomes synergistically reshape sepsis immune homeostasis by modulating neutrophil fate and blocking PD-1/PD-L1. [Abstract]

2026 May 14:102819. PMID: 42140195
Br J Pharmacol

Antidiabetic DPP4 inhibitor Attenuates Intervertebral Disc Degeneration via Macrophage-Nucleus Pulposus Cell Crosstalk. [Abstract]

2026 Jan 15. PMID: 41540645
Int Immunopharmacol

The active ingredient Monotropein in Morinda officinalis alleviates neuroinflammation via inhibiting cGAS/STING signaling pathway. [Abstract]

2026 Aug 15:183:116862. PMID: 42150287
Sci Rep

Probenecid relieves LPS-induced neuroinflammation by modulating the NLRP1 inflammasome pathway in BV2 cells. [Abstract]

2025 Oct 8;15(1):35192. PMID: 41062518

Lipopolysaccharides, from E. coli O111:B4 purchased from MedChemExpress. Usage Cited in: Sci Rep. 2025 Oct 8;15(1):35192. [Abstract]

mRNA levels of TNF-α and IL-1β in LPS-induced (1.6 µg/mL, 24 h) BV2 cells. Data are presented as mean ± SD (n = 3).

Lipopolysaccharides, from E. coli O111:B4 purchased from MedChemExpress. Usage Cited in: Sci Rep. 2025 Oct 8;15(1):35192. [Abstract]

LPS (1.6 µg/mL, 24 h). Two different morphological phenotypes of BV2 cells.

Lipopolysaccharides, from E. coli O111:B4 purchased from MedChemExpress. Usage Cited in: Sci Rep. 2025 Oct 8;15(1):35192. [Abstract]

LPS (1.6 µg/mL, 24 h). The migration capacity of BV2 cells was assessed using a wound-healing assay.

Lipopolysaccharides, from E. coli O111:B4 purchased from MedChemExpress. Usage Cited in: Sci Rep. 2025 Oct 8;15(1):35192. [Abstract]

LPS (1.6 µg/mL, 24 h). ROS levels were determined using FCM in BV2 cells. Data are presented as mean ± SD (n = 3).

Lipopolysaccharides, from E. coli O111:B4 purchased from MedChemExpress. Usage Cited in: Sci Rep. 2025 Oct 8;15(1):35192. [Abstract]

LPS (1.6 µg/mL, 24 h). NLRP1, ASC, and Caspase-1 expression levels in BV2 cells were assessed by WB.
Front Biosci (Landmark Ed)

Formulating Spray-Dried Albumin-Modified Lipid Nanoparticles Encapsulating Acyclovir for Enhanced Pulmonary Drug Delivery. [Abstract]

2024 Oct 22;29(10):363. PMID: 39473424
SSRN

2026 Mar 3.

Solvent & Solubility

In Vitro:

H₂O : 1 mg/mL (ultrasonic and warming and heat to 60°C; DMSO can inactivate Lipopolysaccharides, from E. coli O111:B4's activity)

View the Complete Stock Solution Preparation Table

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (297 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Kabanov DS, et al. Structural analysis of lipopolysaccharides from Gram-negative bacteria. Biochemistry (Mosc). 2010 Apr;75(4):383-404. [Content Brief]

[2]. Ying Liu, et al. Podocyte-Released Migrasomes in Urine Serve as an Indicator for Early Podocyte Injury. Kidney Dis (Basel). 2020 Nov;6(6):422-433. [Content Brief]

[3]. Heinrichs DE, et al. Molecular basis for structural diversity in the core regions of the lipopolysaccharides of Escherichia coli and Salmonella enterica. Mol Microbiol. 1998 Oct;30(2):221-32. [Content Brief]

[4]. Cai KC, et al. Age and sex differences in immune response following LPS treatment in mice. Brain Behav Immun. 2016 Nov;58:327-337. [Content Brief]

[5]. Vogel DY, et al. Human macrophage polarization in vitro: maturation and activation methods compared. Immunobiology. 2014 Sep;219(9):695-703 [Content Brief]

[6]. Arioz BI, et al. Melatonin Attenuates LPS-Induced Acute Depressive-Like Behaviors and Microglial NLRP3 Inflammasome Activation Through the SIRT1/Nrf2 Pathway. Front Immunol. 2019 Jul 2;10:1511. [Content Brief]

[7]. Tezcan G, et al. Azithromycin and Ceftriaxone Differentially Activate NLRP3 in LPS Primed Cancer Cells. Int J Mol Sci. 2022 Aug 22;23(16):9484. [Content Brief]

[8]. Rialdi A, et al. Topoisomerase 1 inhibition suppresses inflammatory genes and protects from death by inflammation. Science. 2016 May 27;352(6289):aad7993. [Content Brief]

[9]. Mohamadi-Zarch SM, et al. Esculetin Alleviates Acute Liver Failure following Lipopolysaccharide/D-Galactosamine in Male C57BL/6 Mice. Iran J Med Sci. 2021 Sep;46(5):373-382. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

Lipopolysaccharides, from E. coli O111:B4

6 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Lipopolysaccharides, from E. coli O111:B4

Publications Citing Use of MedChemExpress (MCE) Lipopolysaccharides, from E. coli O111:B4

All Toll-like Receptor (TLR) Isoforms

Biological Activity

Chemical Information

Publications (6)

Solvent & Solubility

Purity & Documentation

References

Calculators

Help & FAQs

Lipopolysaccharides, from E. coli O111:B4 Related Classifications

HY-D1056A1 Related Classifications